![validity of mmpi-2 validity of mmpi-2](https://www.frontiersin.org/files/Articles/459785/fpsyt-10-00389-HTML/image_m/fpsyt-10-00389-t001.jpg)
This recommendation applies despite the attractive pharmacological and genetic rationale for targeting voltage-gated calcium channels. We conclude that there is moderate evidence of the efficacy of gabapentinoids in anxiety states, but minimal evidence in bipolar disorder and insomnia and they should be used for these disorders only with strong justification. Notably, pregabalin (SMD -0.55, 95% CI -0.92 to -0.18) and gabapentin (SMD -0.92, 95% CI -1.32 to -0.52) were more effective than placebo in reducing preoperative anxiety. Across the anxiety spectrum, a consistent but not universal effect in favour of gabapentinoids compared to placebo was seen (standardised mean difference ranging between -2.25 and -0.25). A quantitative synthesis could not be performed due to heterogeneity in the study population, design and outcome measures. For bipolar disorder, four double-blind RCTs investigating gabapentin, and no double-blind RCTs investigating pregabalin, were identified. Fifty-five double-blind randomised controlled trials (RCTs) and 15 open-label studies were identified.
![validity of mmpi-2 validity of mmpi-2](https://www.gulfbend.org/images/root/MMPI-2.jpg)
We conducted a systematic review and meta-analysis of the evidence for three of their common psychiatric uses: bipolar disorder, anxiety, and insomnia. Many of these uses are off-label for psychiatric indications, and there is increasing concern about their safety, so it is particularly important to have good evidence to justify this usage. Initially licensed for pain and seizures, they have become widely prescribed drugs. It is important to note that, in almost all cases, the magnitude of these differences was small and not clinically significant.The gabapentinoids, gabapentin, and pregabalin, target the α 2δ subunits of voltage-gated calcium channels. A number of MMPI-2 scales evidenced bias reflecting minor underprediction of psychopathology in African Americans. To identify potential bias, the authors conducted 65 step-down hierarchical multiple regression analyses, predicting conceptually relevant clinical criteria from either MMPI-2 clinical or content scales for each gender. These were generally consistent with differences between the groups, indicated by the available extratest criterion data. Mean differences were found on several MMPI-2 validity and clinical scales. It is important to note that, in almost all cases, the magnitude of these differences was small and not clinically significant.ĪB - This study investigated ethnic differences on the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) in 229 African American and 1,558 Caucasian psychiatric inpatients. N2 - This study investigated ethnic differences on the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) in 229 African American and 1,558 Caucasian psychiatric inpatients. T1 - A comparison of MMPI-2 validity in African American and Caucasian psychiatric inpatients